Table 2.
Outcomes of subjects with varicella zoster reactivation after SARS-CoV-2 vaccine (33 studies) or COVID-19 disease (22 studies).
| SARS-CoV-2 vaccine (n = 179*) | COVID-19 disease (n = 39) | |
|---|---|---|
| Latency, median (interquartile range) | 6 (3–10) | 7 (5–20) |
| Varicella zoster virus manifestationsa, n (%) | 177 | 41 |
| Uncomplicated infections, events | 157 (88.7) | 31 (75.6) |
| Dermatomal herpes zoster rash | 153 (86.4) | 28 (68.3) |
| Disseminated rash | 4 (2.3) | 3 (7.3) |
| Serious infections, events | 20 (11.3) | 10 (24.4) |
| Herpes Zoster ophthalmicus | 10 (5.6) | 7 (17.1) |
| Post-herpetic neuralgia | 6 (3.4) | 1 (2.4) |
| Encephalitis-meningitis | 1 (0.5) | 1 (2.4) |
| Vasculitis | 1 (0.5) | 1 (2.4) |
| Acute retinal necrosis | 1 (0.5) | 0 |
| Ramsay-Hunt Syndrome | 1 (0.5) | 0 |
| Pneumonia | 0 | 0 |
| VZV treatment, n (%) | ||
| Pharmacological treatment, patients | 157 | 34 |
| Received treatment | 151 (96.2) | 30 (88.2) |
| No treatment | 6 (3.8) | 4 (11.8) |
| Antiviral treatment, prescriptionsb | 160 | 31 |
| Acyclovir | 20 (12.5) | 19 (61.3) |
| Valacyclovir | 51 (31.9) | 11 (35.5) |
| Famciclovir | 1 (0.6) | 1 (3.2) |
| Ganciclovir | 1 (0.6) | 0 |
| Brivudine | 1 (0.6) | 0 |
| NR antiviral | 86 (53.8) | 0 |
⁎
Six vaccinated subjects also had previous COVID-19 disease.
a
Manifestations reported in SARS-CoV-2 vaccination group (177 events in 175 subjects) and COVID-19 disease group (41 events in 39 subjects).
b
Antiviral prescriptions reported in SARS-CoV-2 vaccination group (160 prescriptions in 151 subjects) and COVID-19 disease group (31 prescriptions in 30 subjects).